What Happened?
Shares of healthcare distributor and services company McKesson (NYSE:MCK) jumped 2.7% in the afternoon session after the company inked a deal with Walmart and USAntibiotics, the nation's only manufacturer of amoxicillin.
Under the agreement, McKesson will serve as the national distributor for the U.S.-made antibiotic, which has recently faced shortages. USAntibiotics expects to produce enough amoxicillin to meet 100% of the nation's demand. This strategic deal positions McKesson at the center of a critical domestic supply chain.
After the initial pop the shares cooled down to $725.33, up 2.7% from previous close.
Is now the time to buy McKesson? Access our full analysis report here, it’s free.
What Is The Market Telling Us
McKesson’s shares are not very volatile and have only had 3 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful, although it might not be something that would fundamentally change its perception of the business.
McKesson is up 28.1% since the beginning of the year, and at $725.33 per share, it is trading close to its 52-week high of $735.33 from July 2025. Investors who bought $1,000 worth of McKesson’s shares 5 years ago would now be looking at an investment worth $4,824.
Today’s young investors won’t have read the timeless lessons in Gorilla Game: Picking Winners In High Technology because it was written more than 20 years ago when Microsoft and Apple were first establishing their supremacy. But if we apply the same principles, then enterprise software stocks leveraging their own generative AI capabilities may well be the Gorillas of the future. So, in that spirit, we are excited to present our Special Free Report on a profitable, fast-growing enterprise software stock that is already riding the automation wave and looking to catch the generative AI next.